Clinic
Columbia Hospital at Medical City Dallas Subsidiary LP
Columbia Hospital at Medical City Dallas Subsidiary LP was paid $21.49M by Medicaid between Jul 2019 and Dec 2024, across 139 billing codes. Its largest line is 99283, emergency room visit (moderate) — 43% of everything it billed.
33Billing provider infoCOLUMBIA HOSPITAL AT MEDICAL CITY DALLAS SUBSIDIARY LP
DALLAS, TX 75230
DALLAS, TX 75230
33aNPI1689628984assigned 05/20/2006
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$21.49M
24GClaims332,474
24DCodes billed139
24AFirst – last monthJul 2019 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#21 of 320
Median peer was paid$205K
This provider vs. median105×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 58 | $301.84 | |
| 2020 | 12,573 | $562K | |
| 2021 | 69,353 | $4.38M | |
| 2022 | 107,315 | $6.51M | |
| 2023 | 94,319 | $6.78M | |
| 2024incomplete | 48,856 | $3.25M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 43% | 52,815 | 51,463 | $9.18M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 30% | 19,972 | 18,675 | $6.38M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7.7% | 9,594 | 9,456 | $1.65M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.3% | 5,699 | 5,009 | $498K |
| 80053 | Comprehensive metabolic panel | 2.1% | 15,660 | 12,678 | $456K |
| 87400 | 1.3% | 16,315 | 15,895 | $275K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.2% | 16,148 | 15,784 | $265K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.1% | 1,638 | 1,576 | $229K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,902 | 6,679 | $188K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | <1% | 2,384 | 2,097 | $166K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 10,511 | 10,364 | $155K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,509 | 4,411 | $150K |
127 more codes
| 85027 | <1% | 24,759 | $142K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,318 | $135K |
| 87070 | <1% | 8,528 | $133K | |
| 86171 | <1% | 5,227 | $117K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,856 | $99K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,821 | $83K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,094 | $79K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 281 | $73K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,186 | $70K |
| 86833 | <1% | 619 | $67K | |
| G0378 | Hospital observation service, per hour | <1% | 185 | $65K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,476 | $60K |
| 74018 | <1% | 1,979 | $57K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 306 | $49K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,985 | $48K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 450 | $32K |
| 81003 | <1% | 6,824 | $29K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,937 | $28K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 604 | $28K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 800 | $25K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 450 | $24K |
| 84703 | <1% | 3,812 | $23K | |
| 81001 | <1% | 7,719 | $22K | |
| 86850 | <1% | 1,015 | $19K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 366 | $18K |
| 87040 | <1% | 1,466 | $17K | |
| 86140 | <1% | 1,725 | $16K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,385 | $15K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 748 | $15K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 491 | $14K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,782 | $14K |
| 84702 | <1% | 1,085 | $13K | |
| 84484 | <1% | 3,367 | $13K | |
| 81025 | <1% | 1,371 | $12K | |
| 76801 | <1% | 141 | $12K | |
| 80047 | <1% | 415 | $12K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 187 | $11K |
| 76830 | Ultrasound, transvaginal | <1% | 191 | $10K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,514 | $10K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 169 | $10K |
| 86832 | <1% | 161 | $9K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 237 | $9K |
| 87799 | <1% | 1,057 | $8K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 133 | $7K |
| 80197 | <1% | 2,577 | $7K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 104 | $7K |
| 83735 | <1% | 4,083 | $7K | |
| 83880 | <1% | 1,426 | $6K | |
| 83690 | <1% | 2,848 | $6K | |
| 87077 | <1% | 412 | $5K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,256 | $5K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 12 | $5K |
| 86900 | <1% | 2,213 | $5K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 136 | $5K |
| 85610 | <1% | 2,412 | $4K | |
| 86901 | <1% | 2,212 | $4K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 805 | $4K |
| 85730 | <1% | 2,076 | $4K | |
| 80061 | Lipid panel | <1% | 816 | $4K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 64 | $3K |
| 83605 | <1% | 813 | $3K | |
| 84100 | <1% | 3,165 | $3K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 109 | $3K |
| 74019 | <1% | 110 | $3K | |
| 11043 | <1% | 26 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 795 | $2K |
| 82570 | <1% | 2,294 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 120 | $2K |
| 73560 | <1% | 42 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,415 | $2K |
| 80320 | <1% | 444 | $2K | |
| 87186 | <1% | 436 | $2K | |
| 87275 | <1% | 56 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,005 | $2K |
| 59025 | Fetal non-stress test | <1% | 126 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 739 | $2K |
| 87797 | <1% | 80 | $2K | |
| 84156 | <1% | 2,170 | $2K | |
| 87497 | <1% | 129 | $1K | |
| J3490 | Unclassified drugs | <1% | 570 | $1K |
| 80143 | <1% | 400 | $1K | |
| 87205 | <1% | 285 | $1K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 224 | $1K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 14 | $1K |
| 96376 | <1% | 106 | $960.00 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 40 | $892.36 |
| 80179 | <1% | 442 | $864.66 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 364 | $857.69 |
| 88342 | <1% | 26 | $823.05 | |
| 83970 | <1% | 155 | $779.77 | |
| 94644 | <1% | 25 | $741.47 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 469 | $481.50 |
| 73610 | <1% | 13 | $472.99 | |
| 73130 | <1% | 14 | $468.44 | |
| 73090 | <1% | 28 | $468.08 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 231 | $467.94 |
| 72131 | <1% | 12 | $447.63 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 50 | $444.80 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,153 | $440.97 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 54 | $416.10 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 40 | $413.91 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 862 | $328.60 |
| 77080 | <1% | 28 | $326.40 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 70 | $305.10 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,820 | $294.85 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 556 | $275.81 |
| J7999 | Compounded drug, not otherwise classified | <1% | 13 | $143.58 |
| 80076 | <1% | 202 | $139.85 | |
| 87276 | <1% | 56 | $135.00 | |
| 86645 | <1% | 69 | $98.55 | |
| 86644 | <1% | 69 | $84.18 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 95 | $82.78 |
| 82565 | <1% | 12 | $53.64 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 63 | $39.53 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 235 | $31.36 |
| 86803 | <1% | 33 | $27.83 | |
| 85378 | <1% | 14 | $25.13 | |
| 87340 | <1% | 16 | $20.15 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 106 | $5.43 |
| A9270 | Non-covered item or service | <1% | 1,883 | $3.60 |
| J2704 | Injection, propofol, 10 mg | 0% | 213 | $0.00 |
| C1769 | Guide wire | 0% | 152 | $0.00 |
| 82803 | 0% | 15 | $0.00 | |
| J1815 | Injection, insulin, per 5 units | 0% | 17 | $0.00 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | 0% | 174 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 79 | $0.00 |
| 93356 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialREDDEN, CHASE (CFO)